The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Open accessAbstract
Recently, we and others identified the microRNA miR-34a as a target of the tumor suppressor gene product p53. Ectopic miR-34a induces a G(1) cell cycle arrest, senescence and apoptosis. Here we report that miR-34a expression is silenced in several types of cancer due to aberrant CpG methylation of its promoter. 19 out of 24 (79.1%) primary prostate carcinomas displayed CpG methylation of the miR-34a promoter and concomitant loss of miR-34a expression. CpG methylation of the miR-34a promoter was also detected in breast (6/24; 25%), lung (7/24; 29.1%), colon (3/23; 13%), kidney (3/14; 21.4%), bladder (2/6; 33.3%) and pancreatic (3/19; 15.7%) carcinoma cell lines, as well as in melanoma cell lines (19/44; 43.2%) and primary melanoma (20/32 samples; 62.5%). Silencing of miR-34a was dominant over its transactivation by p53 after DNA damage. Re-expression of miR-34a in prostate and pancreas carcinoma cell lines induced senescence and cell cycle arrest at least in part by targeting CDK6. These results show that miR-34a represents a tumor suppressor gene which is inactivated by CpG methylation and subsequent transcriptional silencing in a broad range of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
(2008) · doi:10.1038/nrg2290 · Cited by 5,199
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
The power and the promise of DNA methylation markers
Laird, P. W. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1045 · Cited by 1,562
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes
Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., Zhai, Y., Giordano, T. J., Qin, Z. S., Moore, B. B., et al. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.068 · Cited by 1,123
Cited by
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236
Self-citationMicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
A Brief Review on the Mechanisms of miRNA Regulation
Cai, Y., Yu, X., Hu, S., & Yu, J. (2009) · Genomics, Proteomics & Bioinformatics · doi:10.1016/s1672-0229(08)60044-3 · Cited by 1,001
MicroRNAs — the micro steering wheel of tumour metastases
Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S., & Calin, G. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2619 · Cited by 749
miR-34 – a microRNA replacement therapy is headed to the clinic
Bader, A. G. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00120 · Cited by 728
MicroRNA function in cancer: oncogene or a tumor suppressor?
Shenouda, S. K., & Alahari, S. K. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9188-5 · Cited by 682
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0655 · Cited by 677
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
Biological functions of microRNAs: a review
Huang, Y., Shen, X. J., Zou, Q., Wang, S. P., Tang, S. M., & Zhang, G. Z. (2011) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-010-0050-6 · Cited by 652
MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Li, Y., Guessous, F., Zhang, Y., DiPierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L., Jiang, J., Yang, Y., Schmittgen, T. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0529 · Cited by 614
Sato, F., Tsuchiya, S., Meltzer, S. J., & Shimizu, K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08089.x · Cited by 588
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518
Self-citationMir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
Graur, D., Zheng, Y., Price, N., Azevedo, R. B. R., Zufall, R. A., & Elhaik, E. (2013) · Genome Biology and Evolution · doi:10.1093/gbe/evt028 · Cited by 478
Aberrant Regulation and Function of MicroRNAs in Cancer
Adams, B. D., Kasinski, A. L., & Slack, F. J. (2014) · Current Biology · doi:10.1016/j.cub.2014.06.043 · Cited by 471
MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review
Catto, J. W. F., Alcaraz, A., Bjartell, A. S., De Vere White, R., Evans, C. P., Fussel, S., Hamdy, F. C., Kallioniemi, O., Mengual, L., Schlomm, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.044 · Cited by 469
microRNA Therapeutics in Cancer — An Emerging Concept
Shah, M. Y., Ferrajoli, A., Sood, A. K., Lopez-Berestein, G., & Calin, G. A. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.017 · Cited by 453
MicroRNA: A signature for cancer progression
Hussen, B. M., Hidayat, H. J., Salihi, A., Sabir, D. K., Taheri, M., & Ghafouri-Fard, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111528 · Cited by 393
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer
Lopez-Serra, P., & Esteller, M. (2012) · Oncogene · doi:10.1038/onc.2011.354 · Cited by 360
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application
Slaby, O., Svoboda, M., Michalek, J., & Vyzula, R. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-102 · Cited by 356
The p53/miR-34 axis in development and disease
Rokavec, M., Li, H., Jiang, L., & Hermeking, H. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju003 · Cited by 354
Self-citationp53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC
Christoffersen, N. R., Shalgi, R., Frankel, L. B., Leucci, E., Lees, M., Klausen, M., Pilpel, Y., Nielsen, F. C., Oren, M., & Lund, A. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.109 · Cited by 352
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer
Gallardo, E., Navarro, A., Viñolas, N., Marrades, R. M., Diaz, T., Gel, B., Quera, A., Bandres, E., Garcia-Foncillas, J., Ramirez, J., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp219 · Cited by 342
Oxidative stress in apoptosis and cancer: an update
Matés, J. M., Segura, J. A., Alonso, F. J., & Márquez, J. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0906-3 · Cited by 341
Zhao, T., Li, J., & Chen, A. F. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00192.2010 · Cited by 329
Non-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Vogt, M., Munding, J., Grüner, M., Liffers, S.-T., Verdoodt, B., Hauk, J., Steinstraesser, L., Tannapfel, A., & Hermeking, H. (2011) · Virchows Archiv · doi:10.1007/s00428-010-1030-5 · Cited by 309
Self-citationFrequent Downregulation of miR-34 Family in Human Ovarian Cancers
Corney, D. C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2642 · Cited by 308
Self-citationp53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling
Kim, N. H., Kim, H. S., Kim, N.-G., Lee, I., Choi, H.-S., Li, X.-Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001744 · Cited by 308
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
Guessous, F., Zhang, Y., Kofman, A., Catania, A., Li, Y., Schiff, D., Purow, B., & Abounader, R. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10987 · Cited by 306
Krzeszinski, J. Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T.-C., Xie, X.-J., He, L., Mangala, L. S., Lopez-Berestein, G., et al. (2014) · Nature · doi:10.1038/nature13375 · Cited by 303
RetractedRole of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming
Ong, A. L. C., & Ramasamy, T. S. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.004 · Cited by 301
A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression
Okada, N., Lin, C.-P., Ribeiro, M. C., Biton, A., Lai, G., He, X., Bu, P., Vogel, H., Jablons, D. M., Keller, A. C., et al. (2014) · Genes & Development · doi:10.1101/gad.233585.113 · Cited by 297
Genome-Wide Epigenetic Regulation of miRNAs in Cancer
Baer, C., Claus, R., & Plass, C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3731 · Cited by 297
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Hwang, J.-H., Voortman, J., Giovannetti, E., Steinberg, S. M., Leon, L. G., Kim, Y.-T., Funel, N., Park, J. K., Kim, M. A., Kang, G. H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010630 · Cited by 290
MicroRNA-34a: a potential therapeutic target in human cancer
Li, X. J., Ren, Z. J., & Tang, J. H. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.270 · Cited by 287
Bao, B., Ahmad, A., Azmi, A. S., Ali, S., & Sarkar, F. H. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1425s61 · Cited by 286
miR-34a as part of the resistance network in chronic lymphocytic leukemia
Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Bühler, A., Kienle, D., Winkler, D., Dürig, J., van Oers, M. H. J., Mertens, D., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172254 · Cited by 273
Wang, X., Liu, P., Zhu, H., Xu, Y., Ma, C., Dai, X., Huang, L., Liu, Y., Zhang, L., & Qin, C. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.08.006 · Cited by 271
DNA methylation and microRNA dysregulation in cancer
Suzuki, H., Maruyama, R., Yamamoto, E., & Kai, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.007 · Cited by 271
Micromarkers: miRNAs in cancer diagnosis and prognosis
Ferracin, M., Veronese, A., & Negrini, M. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.11 · Cited by 266
Alternative mechanisms of miR-34a regulation in cancer
Slabáková, E., Culig, Z., Remšík, J., & Souček, K. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.495 · Cited by 264
GAMBARI, R., BROGNARA, E., SPANDIDOS, D. A., & FABBRI, E. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3503 · Cited by 262
Nalls, D., Tang, S.-N., Rodova, M., Srivastava, R. K., & Shankar, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024099 · Cited by 256
MicroRNA in ischemic stroke etiology and pathology
Rink, C., & Khanna, S. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2010 · Cited by 255
Agostini, M., & Knight, R. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1825 · Cited by 254
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
Mudduluru, G., Ceppi, P., Kumarswamy, R., Scagliotti, G. V., Papotti, M., & Allgayer, H. (2011) · Oncogene · doi:10.1038/onc.2011.13 · Cited by 252
Intact p53-Dependent Responses in miR-34–Deficient Mice
Concepcion, C. P., Han, Y.-C., Mu, P., Bonetti, C., Yao, E., D'Andrea, A., Vidigal, J. A., Maughan, W. P., Ogrodowski, P., & Ventura, A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002797 · Cited by 197
Feng, Y., Huang, W., Meng, W., Jegga, A. G., Wang, Y., Cai, W., Kim, H. W., Pasha, Z., Wen, Z., Rao, F., et al. (2014) · Stem Cells · doi:10.1002/stem.1571 · Cited by 121
The comprehensive landscape of miR-34a in cancer research
Li, S., Wei, X., He, J., Cao, Q., Du, D., Zhan, X., Zeng, Y., Yuan, S., & Sun, L. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09973-3 · Cited by 84
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer
Cekaite, L., Eide, P. W., Lind, G. E., Skotheim, R. I., & Lothe, R. A. (2016) · Oncotarget · doi:10.18632/oncotarget.6390 · Cited by 84
Interplay between the miRNome and the epigenetic machinery: Implications in health and disease
Poddar, S., Kesharwani, D., & Datta, M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25819 · Cited by 57
MicroRNA in Brain pathology: Neurodegeneration the Other Side of the Brain Cancer
Godlewski, J., Lenart, J., & Salinska, E. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010020 · Cited by 52
The emerging functions of the p53-miRNA network in stem cell biology
Lin, C.-P., Choi, Y. J., Hicks, G. G., & He, L. (2012) · Cell Cycle · doi:10.4161/cc.20207 · Cited by 38
MicroRNAs in B-cells: From normal differentiation to treatment of malignancies
Marques, S. C., Laursen, M. B., Bødker, J. S., Kjeldsen, M. K., Falgreen, S., Schmitz, A., Bøgsted, M., Johnsen, H. E., & Dybkaer, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3057 · Cited by 26
Metadata
- Authors
- Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2008-08-15
- Volume
- 7
- Issue
- 16
- Pages
- 2591-2600
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2156843318
- Cited by
- 784
- References
- 29
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.